.

The following selected journal articles provide valuable and thought-provoking information about interstitial cystitis (IC), and may help you diagnose and treat this urological condition.

Interstitial Cystitis Library

Ajibona OO, Kehinde EO. Interstitial cystitis: a review of current concepts of aetiology, diagnosis and therapy. Scand J Urol Nephrol. 2003;37:253-258.


Bouchelouche K, Nordling J. Recent developments in the management of interstitial cystitis. Curr Opin Urol. 2003;13:309-313.


Clemons JL, Arya LA, Myers DL. Diagnosing interstitial cystitis in women with chronic pelvic pain. Obstet Gynecol. 2002;100:337-341.


Daha LK, Riedl CR, Hohlbrugger G, Knoll M, Engelhardt PF, Pflüger H. Comparative assessment of maximal bladder capacity, 0.9% NaCl versus 0.2 M KCl, for the diagnosis of interstitial cystitis: a prospective controlled study. J Urol. 2003;170:807-809.


Fetner WT, ed. The Female Patient. Chatham, NJ: Quadrant HealthCom Inc; May 2003 supplement.


Hanno PM. Analysis of long-term Elmiron therapy for interstitial cystitis. Urology. 1997;49(suppl 5A):93-99.


Hanno PM, Landis JR, Matthews-Cook Y, Kusek J, Nyberg J Jr, and the Interstitial Cystitis Database Study Group. The diagnosis of interstitial cystitis revisited: lessons learned from the National Institutes of Health Interstitial Cystitis Database study. J Urol. 1999;161:553-557.


Kahn B, et al. Management of patients with interstitial cystitis or chronic pelvic pain of bladder origin: a consensus report. Curr Med Res Opin. 2005;21,4:509-516.


Miller JL, Rothman I, Bavendam TG, Berger RE. Prostatodynia and interstitial cystitis: one and the same? Urology. 1995;45:587-590.


Mulholland SG, Sant GR, Hanno P, Staskin DR, Parsons CL. Pentosan polysulfate sodium for therapy of Interstitial Cystitis: a double-blind placebo-controlled clinical study. Urology. 1990;35:552-558.


Nickel JC. Interstitial cystitis—an elusive clinical target? J Urol. 2003;170:816-817.


O'Leary MP, Sant GR, Fowler FJ Jr, Whitmore KE, Spolarich-Kroll J. The interstitial cystitis symptom index and problem index. Urology. 1997;49(suppl 5A):58-63.


Parsons CL. Potassium sensitivity test. Tech Urol. 1996;2:171-173.


Parsons CL, Dell J, Stanford EJ. Increased prevalence of interstitial cystitis; previously unrecognized urologic and gynecologic cases identified using a new symptom questionnaire and intravesical potassium sensitivity. Urology. 2002;60:573-578.


Parsons CL, Dell J, Stanford EJ, Bullen M, Kahn BS, Willems JJ. The prevalence of interstitial cystitis in gynecologic patients with pelvic pain, as detected by intravesical potassium sensitivity. Am J Obstet Gynecol. 2002;187:1395-1400.


Parsons CL, Greenberger M, Gabal L, Bidair M, Barme G. The role of urinary potassium in the pathogenesis and diagnosis of interstitial cystitis. J Urol. 1998;159:1862-1867.


Parsons CL et al. Abnormal urinary potassium metabolism in patients with interstitial cystitis. J Urol. 2005;173:1182-1185.


Rosenberg et al. Early diagnosis and management of interstitial cystitis. Women's Prim Care. 2004;7,9:456-463.


Sant GR. Interstitial cystitis-a urogynecologic perspective. Contemp OB/GYN. June 1998:1-8.



Important Safety Information

  • Contraindications: ELMIRON® is contraindicated in patients with known hypersensitivity to the drug, structurally related compounds, or excipients
  • Anticoagulant Activity: ELMIRON® is a weak anticoagulant (blood thinner) which may increase bleeding. Patients undergoing invasive surgery or having signs/symptoms of underlying coagulopathy or other increased risk of bleeding (due to anticoagulant therapy or high doses of anti-inflammatory drugs) should be evaluated for the risk of hemorrhage
  • Alopecia: In clinical trials of ELMIRON®, alopecia began within the first 4 weeks of treatment. Ninety-seven percent (97%) of the cases of alopecia reported were alopecia areata, limited to a single area on the scalp
  • Use in Pregnancy: ELMIRON® is a Pregnancy Category B drug
  • Most Common Adverse Reactions (frequency 1% to 4%): Alopecia (4%), diarrhea (4%), nausea (4%), headache (3%), rash (3%), dyspepsia (2%), abdominal pain (2%), liver function abnormalities (1%), dizziness (1%)